Mangalam Drugs & Organics Ltd. (MANGALAM) AI Stock Analysis

Top Page

Mangalam Drugs & Organics Ltd.

(NSE:MANGALAM)

Select Model

Rating:50Neutral

Price Target:INR 29.00▲(0.28% Upside)

Action:reiterated

Date:09/16/26

Overall score is held back primarily by weak financial performance (FY2026 losses, negative operating/free cash flow, and higher leverage). This is partially offset by constructive price momentum (above key moving averages and positive MACD), while valuation remains challenged due to negative earnings (negative P/E) and no provided dividend yield.

Positive Factors

Specialty-intermediates portfolioThe company serves pharmaceutical and chemical value chains with specialty intermediates rather than relying on a single finished product. Its downstream derivatives may support broader applications and product-mix flexibility, providing a durable base for industrial customer relationships and future demand.

Negative Factors

Sharp profitability deteriorationThe move from modest FY2025 profitability to a large FY2026 loss shows that earnings are currently weak and volatile. Negative operating margins reduce internal funding capacity, make recovery dependent on improved business conditions, and weaken confidence in near-term profit sustainability.

Mangalam Drugs & Organics Ltd. (MANGALAM) vs. iShares MSCI India ETF (INDA)

Market Cap: INR 523.44M
Dividend Yield: ―
Average Volume (3M): 8,307
Price to Earnings (P/E): -1.2
Beta (1Y): 0.65
Revenue Growth: -22.27%
EPS Growth: -291.72%
Country: India
Employees: 319
Sector: General
Sector Strength: 55
Industry: Drug Manufacturers - Specialty & Generic

Mangalam Drugs & Organics Ltd. Business Overview & Revenue Model

Company Description

Based in Mumbai, India, Mangalam Drugs & Organics Limited, established in 1972, operates as a global pharmaceutical enterprise. The company is engaged in the production and distribution of a diverse range of medications, drugs, and associated pharmac...

How the Company Makes Money

Mangalam Drugs & Organics Ltd. primarily makes money by manufacturing and selling specialty chemical intermediates (including products such as allyl chloride and its derivatives) to business customers. Revenue is generated from (1) domestic sales to...

Mangalam Drugs & Organics Ltd. Financial Statement Overview

Summary

Financial profile is weak and volatile: FY2026 swung to a large net loss with negative EBIT/EBITDA margins and ~13% revenue decline. Cash generation deteriorated (negative operating cash flow and deeply negative free cash flow), and leverage increased meaningfully (debt-to-equity ~1.02), raising near-term financial risk despite positive equity and historically profitable years.

Income Statement

24Negative

Balance Sheet

42Neutral

Cash Flow

30Negative

Financial statement breakdown
Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	2.32B	2.32B	3.18B	3.67B	3.70B	4.47B
Gross Profit	286.30M	232.46M	1.50B	188.12M	287.77M	546.89M
EBITDA	-87.59M	-149.03M	363.25M	174.76M	259.54M	451.84M
Net Income	-382.41M	-444.00M	67.21M	-90.72M	12.70M	196.57M
Balance Sheet
Total Assets	0	3.15B	3.66B	3.34B	3.60B	3.28B
Cash, Cash Equivalents and Short-Term Investments	7.51M	7.01M	25.89M	11.87M	26.88M	19.55M
Total Debt	0	1.05B	962.30M	1.07B	885.47M	879.04M
Total Liabilities	-1.03B	2.12B	2.17B	1.98B	2.08B	1.78B
Stockholders Equity	1.03B	1.03B	1.49B	1.36B	1.52B	1.51B
Cash Flow
Free Cash Flow	19.14M	-208.11M	223.93M	-79.20M	116.09M	-19.60M
Operating Cash Flow	77.10M	-89.12M	425.94M	39.13M	395.23M	257.09M
Investing Cash Flow	-57.59M	-117.25M	-194.72M	-118.27M	-221.72M	-273.26M
Financing Cash Flow	-11.63M	187.49M	-217.12M	52.27M	-166.17M	29.79M

Mangalam Drugs & Organics Ltd. Technical Analysis

Technical Analysis SentimentNegative

Last Price28.92

Price Trends

50DMA30.98Negative

100DMA29.48Negative

200DMA31.02Negative

Market Momentum

MACD-0.63Positive

RSI43.24Neutral

STOCH35.05Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:MANGALAM, the sentiment is Negative. The current price of 28.92 is below the 20-day moving average (MA) of 30.41, below the 50-day MA of 30.98, and below the 200-day MA of 31.02, indicating a bearish trend. The MACD of -0.63 indicates Positive momentum. The RSI at 43.24 is Neutral, neither overbought nor oversold. The STOCH value of 35.05 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:MANGALAM.

Mangalam Drugs & Organics Ltd. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

IN:MANGALAM against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IN:PAR	73Outperform	INR 1.41B	9.73	―	―	9.40%	34.12%
IN:VAISHALI	62Neutral	INR 866.70M	18.83	―	―	3.08%	972.22%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
IN:MANGALAM	50Neutral	INR 457.75M	-1.18	―	―	-22.27%	-291.72%
IN:BIOFILCHEM	47Neutral	INR 471.94M	96.99	―	―	9.31%	-82.71%
IN:VIVIMEDLAB	40Underperform	INR 506.60M	-0.26	―	―	-39.80%	-452.04%
IN:LASA	38Underperform	INR 252.01M	-1.42	―	―	-95.17%	50.07%

* General Sector Average

Performance Comparison

IN:MANGALAM and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IN:MANGALAM	Mangalam Drugs & Organics Ltd.	28.92	-38.26	-56.95%
IN:BIOFILCHEM	Biofil Chemicals & Pharmaceuticals Ltd.	29.00	-11.69	-28.73%
IN:LASA	Lasa Supergenerics Ltd.	5.03	-6.67	-57.01%
IN:PAR	Par Drugs and Chemicals Limited	114.67	12.95	12.73%
IN:VAISHALI	Vaishali Pharma Ltd.	6.42	-3.58	-35.80%
IN:VIVIMEDLAB	Vivimed Labs Limited	6.11	1.21	24.69%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 16, 2026

Mangalam Drugs & Organics Ltd. AI Stock Analysis

Top Page